| Dr Jennifer Day, MD | |
|
3800 Park Nicollet Blvd, St Louis Park, MN 55416-2527 | |
| (952) 993-3123 | |
| (952) 993-3286 |
| Full Name | Dr Jennifer Day |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 10 Years |
| Location | 3800 Park Nicollet Blvd, St Louis Park, Minnesota |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225443419 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Park Nicollet Methodist Hospital | Saint louis park, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Park Nicollet Clinic | 7911819438 | 1529 |
News Archive
A new study provides evidence from lab experiments that a drug already used in people to fight tapeworms might also prove effective against strains of the superbug MRSA, which kills thousands of people a year in the United States.
The class of immunotherapies known as checkpoint inhibitors have proven to be a highly effective and advantageous treatment option for many cancer patients, but they don't work well for everyone, and oncologists have no reliable way to determine in advance which patients are likely to respond to these drugs.
An innovative robotic sample management system developed by the SME-led PMS project carries out complex sample transport operations rapidly and with a high level of reliability. It includes a new transport system based on magnetic hover railway technologies, a new laboratory information system and a special selective analyser. PMS partners are now predicting a substantial market share for their transport system.
NBI Juiceworks has joined forces with two of the leading distributors in Texas: Metroplex Organics, based in the Dallas-Ft. Worth area and Houston-based Bev Source. Both companies will be distributing Drenchers(TM) 100 percent all natural super juices, Fit 'N Lean super juices and all natural Fit 'N Lean Super Blends.
Oasmia Pharmaceutical AB, developer of a new generation of drugs within human and veterinary oncology, announced today the topline findings from a head-to-head comparison study of its lead human cancer product candidate Paclical and Celgene's Abraxane, which show similar pharmacokinetic (PK) profiles of the two products. The study was conducted in women with metastatic breast cancer.
› Verified 3 days ago
| Entity Name | Park Nicollet Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780621904 PECOS PAC ID: 7911819438 Enrollment ID: O20031104000046 |
News Archive
A new study provides evidence from lab experiments that a drug already used in people to fight tapeworms might also prove effective against strains of the superbug MRSA, which kills thousands of people a year in the United States.
The class of immunotherapies known as checkpoint inhibitors have proven to be a highly effective and advantageous treatment option for many cancer patients, but they don't work well for everyone, and oncologists have no reliable way to determine in advance which patients are likely to respond to these drugs.
An innovative robotic sample management system developed by the SME-led PMS project carries out complex sample transport operations rapidly and with a high level of reliability. It includes a new transport system based on magnetic hover railway technologies, a new laboratory information system and a special selective analyser. PMS partners are now predicting a substantial market share for their transport system.
NBI Juiceworks has joined forces with two of the leading distributors in Texas: Metroplex Organics, based in the Dallas-Ft. Worth area and Houston-based Bev Source. Both companies will be distributing Drenchers(TM) 100 percent all natural super juices, Fit 'N Lean super juices and all natural Fit 'N Lean Super Blends.
Oasmia Pharmaceutical AB, developer of a new generation of drugs within human and veterinary oncology, announced today the topline findings from a head-to-head comparison study of its lead human cancer product candidate Paclical and Celgene's Abraxane, which show similar pharmacokinetic (PK) profiles of the two products. The study was conducted in women with metastatic breast cancer.
› Verified 3 days ago
| Entity Name | Group Health Plan Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710924683 PECOS PAC ID: 1759293954 Enrollment ID: O20031105000417 |
News Archive
A new study provides evidence from lab experiments that a drug already used in people to fight tapeworms might also prove effective against strains of the superbug MRSA, which kills thousands of people a year in the United States.
The class of immunotherapies known as checkpoint inhibitors have proven to be a highly effective and advantageous treatment option for many cancer patients, but they don't work well for everyone, and oncologists have no reliable way to determine in advance which patients are likely to respond to these drugs.
An innovative robotic sample management system developed by the SME-led PMS project carries out complex sample transport operations rapidly and with a high level of reliability. It includes a new transport system based on magnetic hover railway technologies, a new laboratory information system and a special selective analyser. PMS partners are now predicting a substantial market share for their transport system.
NBI Juiceworks has joined forces with two of the leading distributors in Texas: Metroplex Organics, based in the Dallas-Ft. Worth area and Houston-based Bev Source. Both companies will be distributing Drenchers(TM) 100 percent all natural super juices, Fit 'N Lean super juices and all natural Fit 'N Lean Super Blends.
Oasmia Pharmaceutical AB, developer of a new generation of drugs within human and veterinary oncology, announced today the topline findings from a head-to-head comparison study of its lead human cancer product candidate Paclical and Celgene's Abraxane, which show similar pharmacokinetic (PK) profiles of the two products. The study was conducted in women with metastatic breast cancer.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jennifer Day, MD 3800 Park Nicollet Blvd, St Louis Park, MN 55416-2527 Ph: (952) 993-3123 | Dr Jennifer Day, MD 3800 Park Nicollet Blvd, St Louis Park, MN 55416-2527 Ph: (952) 993-3123 |
News Archive
A new study provides evidence from lab experiments that a drug already used in people to fight tapeworms might also prove effective against strains of the superbug MRSA, which kills thousands of people a year in the United States.
The class of immunotherapies known as checkpoint inhibitors have proven to be a highly effective and advantageous treatment option for many cancer patients, but they don't work well for everyone, and oncologists have no reliable way to determine in advance which patients are likely to respond to these drugs.
An innovative robotic sample management system developed by the SME-led PMS project carries out complex sample transport operations rapidly and with a high level of reliability. It includes a new transport system based on magnetic hover railway technologies, a new laboratory information system and a special selective analyser. PMS partners are now predicting a substantial market share for their transport system.
NBI Juiceworks has joined forces with two of the leading distributors in Texas: Metroplex Organics, based in the Dallas-Ft. Worth area and Houston-based Bev Source. Both companies will be distributing Drenchers(TM) 100 percent all natural super juices, Fit 'N Lean super juices and all natural Fit 'N Lean Super Blends.
Oasmia Pharmaceutical AB, developer of a new generation of drugs within human and veterinary oncology, announced today the topline findings from a head-to-head comparison study of its lead human cancer product candidate Paclical and Celgene's Abraxane, which show similar pharmacokinetic (PK) profiles of the two products. The study was conducted in women with metastatic breast cancer.
› Verified 3 days ago
Karla Susan Rosenman, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3800 Park Nicollet Blvd, Dermatology 4th Floor, St Louis Park, MN 55416 Phone: 952-993-3821 | |
Dr. Alison M Lang, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3800 Park Nicollet Blvd, St Louis Park, MN 55416 Phone: 952-993-3789 | |
Anne B Neeley, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3800 Park Nicollet Blvd, St Louis Park, MN 55416 Phone: 952-993-3123 Fax: 952-993-3286 | |
Allison L Schini, Dermatology Medicare: Accepting Medicare Assignments Practice Location: Park Nicollet Clinic - Slp, 3800 Park Nicollet Blvd Admin 7n, St Louis Park, MN 55416 Phone: 952-993-3260 Fax: 952-993-0333 | |
Dr. Larisa Sotinsky Speetzen, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3800 Park Nicollet Blvd, St Louis Park, MN 55416 Phone: 952-993-1000 | |
Dr. Rachel S Hub, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3800 Park Nicollet Blvd, St Louis Park, MN 55416 Phone: 952-993-3789 | |
Michael Macaulay, Dermatology Medicare: Not Enrolled in Medicare Practice Location: 3800 Park Nicollet Blvd, St Louis Park, MN 55416 Phone: 952-993-3789 |